文献速递腹部MRCT

定量DCE-MRI早期评估胰腺导管腺癌化疗反应

Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma.
PubMed 文献 · Eur Radiol · 2026-08-22

结果显示,Ktrans早期变化在所有药代动力学模型下均可区分化疗反应者与无反应者,体模校正后扩展Tofts模型的预测准确率可达98%。

要点

  • 体模校正后的ΔKtrans在扩展Tofts模型中预测化疗反应准确率达98%,可用于早期疗效判断
  • 治疗7±2周时定量DCE-MRI即可预测17±4周肿瘤反应,早于形态学变化
  • 常规RECIST CT评估在8±2周仅能识别17%的反应者,DCE-MRI明显更敏感

核心结论

  • 定量DCE-MRI可在胰腺导管腺癌化疗早期高准确度预测治疗反应
  • 便携式灌注体模校正可进一步提高预测可靠性
  • 该方法可作为支持胰腺癌及时个体化治疗决策的前瞻性验证影像生物标志物

研究设计与样本

  • 42例完成基线MRI(化疗前1±1周)及化疗开始后7±2周MRI随访
  • 以17±4周时改良RECIST评估肿瘤反应,定义为肿瘤缩小>10%

关键影像表现/征象

  • 体模校正后ΔKtrans在扩展Tofts模型下预测准确率提高至98%
  • 所有药代动力学模型中ΔKtrans均可显著区分化疗反应者与无反应者
  • 未经体模校正时ΔKtrans预测准确率约为80%

诊断标准与关键数值

  • 治疗反应评估采用改良RECIST标准,反应者定义为肿瘤缩小>10%
  • 受试者工作特征曲线用于评估药代动力学参数早期变化的预测准确性
  • 体模校正前ΔKtrans在所有药代动力学模型下预测准确率约80%
  • 体模校正后ΔKtrans在扩展Tofts模型下预测准确率达98%

临床应用与阅片要点

  • 定量DCE-MRI的ΔKtrans可作为胰腺癌化疗早期疗效预测指标,建议在报告中注明所用药代动力学模型
  • 使用便携式灌注体模可纠正扫描仪依赖性误差,提高多中心或随访检查的可比性
  • 化疗7±2周时DCE-MRI即可预测后期肿瘤反应,有助于临床及时调整治疗方案

局限性

  • 两中心研究,完成完整MRI随访的样本量为42例
  • 本研究仅评估化疗反应,未涵盖其他治疗方式的预测价值

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To prospectively evaluate whether quantitative DCE-MRI can predict early chemotherapy response in pancreatic ductal adenocarcinoma (PDAC), and to assess the added value of a point-of-care portable perfusion phantom (P4) for correcting scanner-dependent errors.

MATERIALS AND METHODS: Fifty-four patients with biopsy-confirmed PDAC were prospectively enrolled at two institutions; 42 completed MRI scans at baseline (1 ± 1 weeks before chemotherapy) and 7 ± 2 weeks after treatment initiation. P4s were imaged concurrently to correct for scanner-dependent measurement errors. Eleven pharmacokinetic (PK) parameters were derived using Tofts, extended Tofts, and shutter speed models. Treatment response at 17 ± 4 weeks was assessed using the modified RECIST, with responders defined as patients with > 10% tumor size reduction. Early changes in PK parameters were analyzed using receiver operating characteristic curves to assess predictive accuracy, and differences between responders and non-responders were assessed using one-way ANOVA.

RESULTS: Among 42 patients (median age 67 years; 27 males), 20 were responders and 22 non-responders. Early changes in Ktrans (ΔKtrans) significantly distinguished responders from non-responders across all PK models, achieving ~80% predictive accuracy before P4 correction. After P4-based correction, ΔKtrans accuracy improved to 98% with the extended Tofts model. In contrast, standard RECIST-based CT assessment at 8 ± 2 weeks identified response in only 17% of patients.

CONCLUSION: Quantitative DCE-MRI enables early, highly accurate prediction of chemotherapy response in PDAC, and P4-based error correction further enhances reliability. This approach offers a prospectively validated imaging biomarker that can support timely, personalized treatment decisions for patients with PDAC.

KEY POINTS: QuestionCan quantitative dynamic contrast-enhanced MRI accurately identify early chemotherapy response in PDAC before conventional morphologic changes become apparent on CT? FindingsP4-corrected quantitative DCE-MRI predicted 17-week tumor response with up to 98% accuracy after only 7 weeks of chemotherapy treatment. Clinical relevanceP4-corrected quantitative DCE-MRI may enable earlier identification of ineffective chemotherapy in pancreatic cancer, supporting timely treatment modification, reducing unnecessary toxicity, and facilitating more personalized patient management.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Holland, Onuoha, Outlaw, et al. Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Eur Radiol. 2026. PMID: 42631739. doi:10.1007/s00330-026-12810-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。